TOP TIERMARKET NEWSWIRE

News & sentiment

IMMUNITYBIO INC (IBRX) — News & AI sentiment

IMMUNITYBIO INC (IBRX) news roundup. 2 stories in the past week, 7 over 30 days. Average 30-day sentiment is 52.1/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 4 sales totalling $3.8M — net selling of $3.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

2

avg sentiment 46.5/100

30d stories

7

avg sentiment 52.1/100

Insider net (90d)

$3.8M

0 buys · 4 sells

Congress (90d)

0

0 buys · 0 sells

IBRX news in the last 24 hours, 7 days, 30 days and 90 days

How much IBRX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	IBRX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	2	46.5/100	IBRX headlines →
Last 30 days	7	52.1/100	IBRX headlines →
Last 90 days	34	58.4/100	IBRX headlines →

Latest stories on IBRX

IBRX Stock Eyes Worst Week Since July: New Patent Eyes Broader Anktiva Use Ahead Of Lung Cancer Conference

Stocktwits News58 · neutralproduct/pr

2d ago

ImmunityBio put volume heavy and directionally bearish

The Fly35 · bearishgeneral

4d ago

ImmunityBio: None Of The Moonshots Is Priced In

Seeking Alpha63 · neutralproduct/pr

Sep 3

IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update

Stocktwits News67 · bullishproduct/pr

Aug 27

ImmunityBio: ANKTIVA Is Real, The Valuation Isn't

Seeking Alpha38 · neutralgeneral

Aug 26

SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon

Stocktwits News56 · neutralgeneral

Aug 26

IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push

Stocktwits News48 · neutralproduct/pr

Aug 25

SLS And IBRX Eye Green Weekly Close: Vanguard’s Major Stakes In Cancer Drugmakers Steal The Spotlight

Stocktwits News55 · neutralgeneral

Aug 14

Immunitybio Appoints Kim As Vice Chairman

The Fly55 · neutralgeneral

Aug 10

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

StockTitan63 · neutralgeneral

Aug 10

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

Stocktwits News67 · bullishearnings

Aug 4

ImmunityBio’s Revenue Jump and Global Expansion Highlight a Turning Point Despite Steep Losses August 4, 2026

MarketChameleon58 · neutralproduct/pr

Aug 4

ImmunityBio, Inc. (IBRX) files 8-K

SEC 8-K50 · neutralgeneral

Aug 4

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

StockTitan63 · neutralearnings

Aug 4

IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback

Stocktwits News63 · neutralgeneral

Aug 3

ImmunityBio wins UAE approval for ANKTIVA cancer therapies

TipRanks73 · bullishproduct/pr

Jul 30

ImmunityBio, Inc. (IBRX) files 8-K

SEC 8-K50 · neutralgeneral

Jul 30

ImmunityBio stock jumps on UAE drug approval for ANKTIVA

Investing.com Markets73 · bullishproduct/pr

Jul 30

IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease

Stocktwits News67 · bullishgeneral

Jul 30

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

StockTitan67 · bullishproduct/pr

Jul 29

IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat

Stocktwits News48 · neutralgeneral

Jul 29

IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference

Stocktwits News58 · neutralgeneral

Jul 27

ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)

Seeking Alpha48 · neutralanalyst

Jul 20

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

Seeking Alpha63 · neutralanalyst

Jul 17

ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold

Seeking Alpha56 · neutralanalyst

Jul 16

Open IBRX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →